OPRT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
OPRT is not a good buy right now. With no proprietary buy signals, weakening Q3’25 fundamentals, a bearish forward pattern signal (higher odds of further downside over 1D/1W/1M), and a bearish/limited-upside Wall Street stance (JPM Underweight with a $5.50 target near the current ~$5.46–$5.49), the risk/reward is skewed against an impatient buyer. Best action: sell/avoid new longs at current levels.
Price is trading around the pivot (Pivot 5.475) in pre-market (~5.46–5.49), implying a ‘decision zone’ rather than a clean breakout. Momentum is not convincingly bullish: MACD histogram is slightly positive (0.0423) but contracting, which often signals fading upside momentum. RSI(6) at ~52 is neutral (no strong oversold bounce setup). Moving averages are converging, consistent with consolidation and low directional conviction. Key levels: resistance R1 ~6.07 then R2 ~6.43; supports S1 ~4.88 then S2 ~4.52. The provided pattern-based forecast is notably bearish (70% chance of -6.41% next day, -8.55% next week, -10.14% next month), which tilts the technical read to downside risk despite the mild positive MACD.
Open-interest skew favors calls (OI put/call 0.41), which can be interpreted as comparatively optimistic positioning. Price is sitting near the pivot, so a clean reclaim and hold above ~5.48 with follow-through could target ~6.07 (R1). No recent negative newsflow in the last week reduces immediate headline risk.
with revenue down YoY and profitability/EPS collapsing. Wall Street stance is negative: JPMorgan Underweight with a $5.50 target close to current price implies limited upside. No Intellectia proprietary buy signal today (no AI Stock Picker, no SwingMax). No notable hedge fund or insider accumulation trends recently.
Latest quarter: 2025/Q3. Revenue fell to ~$238.7M (-4.51% YoY). Net income dropped to ~$5.20M (down -117.35% YoY), and EPS fell to $0.11 (-114.67% YoY), indicating a sharp profitability deterioration versus the prior year period. Gross margin slipped to ~76.28% (-1.83% YoY). Overall, growth and earnings trends are negative in Q3’25, which weakens the case for buying now.
Recent analyst action: (2025-12-04) JPMorgan lowered its price target to $5.50 from $6 and maintained an Underweight rating. This signals worsening expectations and suggests Wall Street pros see limited upside from current levels, while cons include pressured fundamentals and a muted outlook for the consumer/specialty finance space. Overall Street takeaway from the provided data: bearish-to-cautious, with the key visible rating being Underweight and a target essentially at the current price.
